Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDF vs ADV in Chinese CHB
NCT01300234Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2011
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tenofovir disoproxil fumarate in Chronic Hepatitis B (CHB) (2 arms), sponsored by GSK. Primary endpoint: Proportion of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <400 Copies/Milliliter (mL) at 48 weeks. Started Mar 2011; status: completed.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT01300234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01300234.